ROCHESTER, Minn. – A drug many were hoping could battle Alzheimer’s seems to have failed — but local doctors say it’s not over yet.
The unsuccessful trial used an antibody called Solanezumab, which many thought would target plaque that builds around our brains and can lead to diseases like Alzheimer’s.
We talked to the director of Alzheimer’s research at Mayo Clinic — and he tells us some questions still need to be answered.
“Is that the best way to attack the protein, is it early enough, should we do it later and when we are still looking at people who have developed the dementia stage of Alzheimer’s — so should we be treating people earlier in the course,” said Ronald Peterson, M.D., Ph.D., Mayo Clinic Alzheimer’s Disease Research Center.
He also said Mayo is doing two research trials of their own when it comes to Alzheimer’s.